10x Genomics, Inc. TXG Accrued expenses and other current liabilities
Accrued expenses and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s accrued expenses and other current liabilities?
- 10x Genomics, Inc. (TXG) reported accrued expenses and other current liabilities of -$6.14M in Q1 2026.
- How has 10x Genomics, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- 10x Genomics, Inc.'s accrued expenses and other current liabilities decreased by 241.7% year-over-year, from $4.33M to -$6.14M.
- What does accrued expenses and other current liabilities mean?
- Measures the net change in short-term obligations owed to third parties, excluding trade payables and compensation. This metric provides insight into the company's working capital management and the timing of cash outflows for various operational expenses.